BRAF (L597V)

BRAF · Variant type: point · HGVS: p.L597V

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Dabrafenib	100.0%	0.0%	94.74
2	Encorafenib	100.0%	0.0%	98.50
3	Ripretinib	98.7%	1.3%	92.95
4	Sorafenib	98.2%	1.8%	96.72
5	Regorafenib	97.2%	2.8%	95.99
6	Ponatinib	97.0%	3.0%	78.23
7	Nilotinib	93.6%	6.4%	96.49
8	Apatinib	92.9%	7.1%	97.73
9	Dasatinib	88.9%	11.1%	87.97
10	Vemurafenib	85.0%	15.0%	96.49
11	Umbralisib	75.8%	24.2%	98.74
12	Pazopanib	75.5%	24.5%	97.49
13	Erdafitinib	71.4%	28.6%	95.71
14	Upadacitinib	65.3%	34.7%	97.98
15	Gedatolisib	65.0%	35.0%	99.75
16	Imatinib	61.4%	38.6%	99.00
17	Pacritinib	56.2%	43.8%	88.64
18	Dacomitinib	43.3%	56.7%	97.99
19	Canertinib	42.2%	57.8%	96.49
20	Vandetanib	36.9%	63.1%	95.74
21	Rabusertib	36.1%	63.9%	98.74
22	Osimertinib	30.6%	69.4%	97.24
23	Ibrutinib	29.5%	70.5%	94.74
24	Abemaciclib	25.9%	74.1%	91.48
25	Gefitinib	24.9%	75.1%	99.25

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Dabrafenib	100.0%	98.3%	+1.7%
Encorafenib	100.0%	98.0%	+1.9%
Ripretinib	98.7%	100.0%	-1.3%
Sorafenib	98.2%	98.5%	-0.3%
Regorafenib	97.2%	98.3%	-1.1%
Ponatinib	97.0%	99.4%	-2.5%
Nilotinib	93.6%	85.8%	+7.8%
Apatinib	92.9%	94.1%	-1.2%
Dasatinib	88.9%	80.6%	+8.3%
Vemurafenib	85.0%	92.8%	-7.8%
Umbralisib	75.8%	65.3%	+10.6%
Pazopanib	75.5%	79.3%	-3.8%
Erdafitinib	71.4%	54.1%	+17.3%
Upadacitinib	65.3%	49.6%	+15.7%
Gedatolisib	65.0%	56.5%	+8.5%
Imatinib	61.4%	—	—
Pacritinib	56.2%	58.5%	-2.3%
Dacomitinib	43.3%	46.6%	-3.3%
Canertinib	42.2%	40.7%	+1.6%
Vandetanib	36.9%	—	—
Rabusertib	36.1%	41.1%	-5.0%
Osimertinib	30.6%	—	—
Ibrutinib	29.5%	—	—
Abemaciclib	25.9%	—	—
Gefitinib	24.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.4ms